PLAINSBORO, N.J., Oct. 17, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the market release of the Integra® Proximal Humeral Fracture Plate System in the United States. The comprehensive system joins a growing portfolio of shoulder fracture solutions, which includes a primary and reverse system with a unique platform press-fit stem.
The Proximal Humeral Fracture Plate System includes two distinctive, anatomic proximal humeral plates in one tray, allowing the surgeon to intra-operatively choose between various fixation options for common to more complex and unique fracture patterns. The two plates are also designed to simplify positioning and minimize soft tissue interference.
The system's Low Profile Plate is designed to be placed lower on the humerus to minimize subacromial and soft tissue impingement, while its Greater Tuberosity Plate provides a higher placement option, with 12 proximal screw holes to maximize the fixation coverage of the humeral head. Both plates include four holes, specifically designed to provide stable fixation in the calcar neck and help protect against varus tilt and settling of the humeral head.
"We are very pleased that we can now offer surgeons a comprehensive portfolio of solutions for shoulder fractures, to help address the individual needs of their patients," said Robert Paltridge, Corporate Vice President, President – Extremity Reconstruction. "Our new system complements the Titan™ Modular Fracture and Reverse Shoulder System, and allows us to further penetrate the growing shoulder market by providing surgeons with multiple options for fracture treatment."
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella Director, Corporate Communications (609) 936-2389 firstname.lastname@example.org
Source:Integra LifeSciences Holdings Corp.